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Abstract 
Advances in the understanding of the Tribbles family of pseudokinases (TRIB1, TRIB2 and TRIB3) 
reveal the potential of these proteins as valuable biomarkers of disease diagnosis, prognosis, 
prediction and clinical strategy. In their role as signalling mediators and scaffolding proteins TRIBs 
lead to changes in protein stability and activity which impact on diverse cellular processes such as 
proliferation, differentiation, cell cycle and cell death. We review the role of TRIB proteins as 
promising therapeutic targets with an emphasis on their role in cancer and as biomarkers with 
potential application across diverse pathological processes.  
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Introduction 
Pseudokinases represent the most well understood class of pseudoenzymes, and carry out many 
critical non-enzymatic roles in physiological and pathological processes. The widely-studied Tribbles 
(TRIB) family of serine/threonine pseudokinases function as important signalling mediators and 
scaffold subunits via the binding and modulation of several signalling molecules, including kinases, 
phosphatases, transcription factors and components of the ubiquitin proteasome system.  
TRIBs have confirmed and proposed functions in a number of cancers, and advances in the 
understanding of both the normal and malignant biology of TRIBs and other pseudokinases reveal the 
potential of these proteins as valuable biomarkers of disease diagnosis, prognosis, prediction and 
clinical strategy. This was first recognised in kidney disease, where in the kidney transplantation 
setting, TRIB1 was established as a biomarker of immune-mediated chronic allograft failure associated 
with a poor prognosis[1]. Another striking example is in blood cancer, where there is a correlation 
between high expression of TRIB2 and anti-apoptotic BCL-2[2], which confers sensitivity to the BH3 
mimetic Venetoclax[3], an emerging novel agent for blood cancer treatment, and highlighting the 
potential of TRIB2 as a predictive biomarker for treatment response in blood cancer patients.  
Further to this, recent studies have addressed the pharmacological targeting of pseudoenzymes with 
pre-approved drugs, repurposing these compounds to achieve novel secondary on-target effects by 
rational selection of potential compounds by function. This approach to drug-discovery highlights the 
potential of utilizing pre-existing, repurposed treatments to achieve positive clinical outcomes while 
minimizing the time and financial constraints traditionally associated with drug development.  
Pseudokinases  
Protein kinases have long since been recognized for their vital roles in the regulation of most 
eukaryotic processes and have been demonstrated to be dysregulated in multiple conditions including 
cancers and neurodegenerative diseases. The primary role of protein kinases is to catalyse transfer of 
a phosphate group from ATP to its substrate, a process which is mediated by a highly conserved kinase 
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domain fold, thus inherently assigning these enzymes a secondary role as an effective and precise 
protein scaffold[4].  
Of more than 500 protein kinases identified in the human kinome, around 10% have been 
subsequently categorised as ‘pseudokinases’[5]. Pseudokinases are vital in the regulation of diverse 
cellular processes, and have known associations with a number of key biological pathways often found 
dysregulated in disease. These pseudoenzymes are less well defined but lack canonical 
phosphotransferase activity and are found throughout distinct kinase subfamilies, suggesting diverse 
evolutionary roots which have been well-reviewed elsewhere[6] and in this special issue. 
Pseudokinases can be further categorized into several groups by their missing residues, and almost 
half have been reported to show residual ATP-binding activity, though this is an area of some debate 
and highly controversial. The pseudokinase JH2 domain of JAK2, for example, binds ATP and shows 
some weak catalytic activity. It is unclear whether this is important for JAK2 function, and indeed 
disruption of ATP-binding in wild type JAK2 does not affect activation, however ameloriates 
hyperactivation of the JAK2 V617F mutant[7], incidentally highlighting the JH2 domain as an 
interesting potential therapeutic target.  
Despite lacking canonical phosphotransferase activity, pseudokinases play key roles in normal and 
disease biology via their function as signal transduction mediators and as protein scaffolds, often 
promoting degradation or stability of their pseudo-substrates by facilitating ubiquitination. In the case 
of the CAMK subfamily ‘Tribbles’, a C-terminal tail docking site with a conserved DQLVP motif regulates 
the activity of COP1 E3 ubiquitin ligase[8,9] and thus the ubiquitination and subsequent degradation 
of target substrates, whereas in other instances TRIB has led to increased substrate stability by 
inhibiting ubiquitination[10]. Additionally, a MEK1 binding site confers a signal transduction role in the 
MAPK pathway. Several pseudokinases have been well-studied in human cells including JAK2 (which 
contains both active kinase and pseudokinase domains)[11], the RAF/mitogen-activated protein 
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kinase (MEK) modulators, ErbB3/HER3[12] and the TRIB family, and many of the 48 pseudokinases 
found in humans have distinct homologues in popular models such as D. Melanogaster and C. Elegans.  
Tribbles in normal physiology 
The three Tribble pseudokinases (TRIB1, TRIB2 and TRIB3) found in the human genome are 
homologues of the Drosophila pseudokinase ‘Tribbles’ (Trbl), and indeed many interactions between 
Tribbles family proteins and their partners are conserved across species. Drosophila Trbl induces 
degradation of the C/EBP transcription factor homolog slbo and the CDC25 phosphatase homolog 
String via the proteasome pathway[13], thereby regulating cell differentiation, proliferation, migration 
and growth, and interacts with the proto-oncogene AKT[14]. 
Evolving from a common ancestor[13], mammalian TRIB pseudokinases are three-domain proteins 
containing an N-terminal PEST region, a highly atypical bi-lobed pseudokinase core (lacking one or 
more canonical catalytic residues) and a C-terminal tail (Figure 1). As with other members of the 
pseudokinase family, there is some debate surrounding the attribution of ATP-binding activity to the 
pseudokinase core of TRIB proteins, and subsequently the relevance of residual ATP-binding affinity 
for function. While TRIB1 is generally recognized as being incompatible with ATP binding which has 
been confirmed by structural studies[9,15], the ATP binding attribution to TRIB2 remains 
controversial. Bailey et al. demonstrated a low affinity of TRIB2 for ATP [16], an interaction reliant 
upon the conserved Lys90 residue, while Murphy et al.[17] conversely saw no nucleotide binding 
properties of a number of pseudokinases including TRIB2 and clarification of the ATP-binding status 
of TRIB2 requires further structural studies. Whether ATP-binding occurs or not, it is not clear that it 
serves a biological function as there is currently no known association between TRIB function and 
catalytic activity.  
Within the C-terminal tail, MEK1 and COP1 binding sites result in TRIB-mediated modulation of the 
MAPK/ERK signal transduction pathway via increased ERK phosphorylation[18], and proteosomal 
degradation by interaction with COP1 E3 ubiquitin ligase[19]. The pseudokinase domain facilitates this 
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E3-mediated degradation of target substrates by anchoring target proteins in close proximity to the 
E3 ligase and of the many roles of TRIB family pseudokinases, COP1-dependent degradation of the 
transcription factor C/EBPα is the best understood[20]. Several studies have provided valuable insight 
into the mechanism of TRIB-mediated degradation of C/EBPα by COP1[15,21,22]. It was demonstrated 
by Jamieson et al. that a significant conformational change of TRIB1 occurred upon C/EBPα binding to 
the pseudokinase core. This conformational change induced allosteric changes which facilitated the 
undocking of the C-terminal COP1 binding motif from the core, releasing autoinhibition to allow for 
COP1 recruitment and COP1-mediated ubiquitination and degradation of C/EBPα (Figure 2). 
TRIB pseudokinases can also stabilise protein substrates by modulating the ubiquitin proteasome 
system as has been demonstrated for TRIB3-mediated inhibition of PML-RARα ubiquitination[10] . 
Modulation of pro-survival AKT/FOXO signalling has also been demonstrated, though the molecular 
mechanisms are yet to be fully understood and different TRIB family members appear to have 
different roles in this pathway (Figure 3); TRIB2 has been shown to enhance AKT signalling and 
promote drug resistance in cancer cells[23], while TRIB3 has been shown to inhibit AKT 
phosphorylation in neuronal cells, driving cell death in Parkinson’s disease[24]. The integration of TRIB 
proteins with signal transduction and degradation pathways (Figure 3) confers multifactorial roles for 
each family member which are highlighted in Error! Reference source not found.. 
One of the first identified roles of mammalian TRIB proteins was in glucose regulation[34] and lipid 
metabolism[37], where it was shown that TRIB3 contributes to insulin resistance by functioning as a 
negative modulator of AKT, and stimulated lipolysis through its association with COP1 E3 ligase. The 
first role for TRIB proteins in haematopoiesis, showed that TRIB2 could control the maturation and 
function of the myeloid and lymphoid lineages in response to cytokines including SCF, G-CSF, GM-CSF, 
and M-CSF[20]. Differential expression of the three TRIB pseudokinases in haematopoietic cells 
highlights non-redundant and lineage-specific functions in this system; TRIB1 is expressed most highly 
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in the myeloid lineage, TRIB2 in the lymphoid lineage and TRIB3 consistently across all haematopoietic 
cells[41].  
Interactions between TRIBs and C/EBP transcription factors (C/EBP     ) underpin their 
importance in cell development and differentiation, as C/EBPs regulate the expression of a diverse 
spectrum of target genes[43]. In the haematopoietic system, TRIB1 and TRIB2 mediate degradation of 
the C/EBPα p42 isoform via polyubiquitination of lysine 48[20], which blocks neutrophil differentiation 
and concurrently increases differentiation of eosinophils, monocytes and macrophages. This 
demonstrates the necessity for a tightly-regulated balance of TRIB expression in normal myeloid 
haematopoiesis[39,40]. This is supported by recent studies showing that TRIB1 regulates early 
eosinophil lineage commitment and cell identity by integrating its role in C/EBPα degradation with IL-
5 signalling[40], and there is strong evidence implicating a role for TRIB3 in quiescence of HSCs[44]. 
By regulating the activity and degradation of proteins including MEK1, MAPKs (p38, ERK, JNK), AKT, 
CDC25, ATF, NF-κB and Wnt/β-catenin TRIBs also regulate cellular function via protein interactions, in 
addition to control of haematopoietic cell development. TRIB1 plays a critical role in macrophage 
migration and driving the polarization and differentiation of M2-like macrophages[42] and 
eosinophils. TRIB proteins regulate innate inflammation signalling[38] via their interaction with NF-κB.  
When we consider then the plethora of processes in which TRIB proteins and indeed many 
pseudokinases are involved, it is not difficult to appreciate the pathological effects which are observed 
upon their dysregulation.  
TRIB pathologies 
As with their catalytically active counterparts many pseudokinases are dysregulated in diseases, and 
TRIB expression can be induced by a range of cellular stresses and mitogens[44,45]. Consequently, 
TRIBs have been shown to play multifactorial roles in numerous cancers, as well as being linked to 
drug resistance via pro-survival and anti-apoptotic pathways[2,23]. Current knowledge indicates both 
oncogenic and tumour suppressive roles of the TRIB family, dependent on family member and cellular 
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context. Error! Reference source not found. highlights some of the known mechanisms by which TRIB 
proteins act in various cancer subtypes. Also outlined are a selection of kinase inhibitors which have 
been tested, either experimentally or by clinical trial, in the indicated type as these represent a 
promising route of investigation with respect to TRIB targeting, as will be discussed in more detail 
later.
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The best understood pathway by which TRIBs promote oncogenesis is their role in degradation of C/EBP 
transcription factors. TRIB1 and TRIB2 degrade the C/EBPα p42 isoform resulting in excess p30, a mechanism 
that mimics what occurs in acute myeloid leukaemia (AML) patients with CEBPA mutations[68]. This 
mechanism of TRIB-mediated degradation of C/EBPα has a key role in the pathogenesis and therapeutic 
response of acute promyelocytic leukaemia, a subtype of AML expressing PML-RAR[47]. Indeed TRIB3 also 
has an important role mediating acute promyelocytic leukaemia tumorigenesis and treatment response via is 
stabilizing effect on the driver oncogene PML-RAR[10]. TRIB2 mRNA expression has been associated with an 
AML poor prognostic subgroup characterised by a dysregulated C/EBPα gene signature[20], but it is not 
associated with the good prognostic CEBPA-mutant subgroup, confirming the clinical importance and 
validation of TRIB2 mechanism. Interestingly, p30 drives AML only in the presence of p42[69], likely due to the 
requirement for p42-directed myeloid differentiation for formation of leukaemia stem cells and myeloid 
leukaemia initiation. Thus, although not mutated itself in AML, TRIB2 represents a highly promising 
therapeutic target in AML with potential application across heterogeneous molecular and cytogenetic 
subgroups. 
Furthermore, TRIBs are known to regulate the Ras-Raf-MEK-ERK mitogen activating kinase pathway, which has 
a well-documented role in signal transduction in both normal and malignant cells[70], and components of this 
pathway and it’s upstream receptors are often found aberrantly expressed or mutated in human cancers[71]. 
In line with this, this pathway is strongly associated with haematopoietic cell proliferation and drug resistance 
in AML, and is regulated via the interaction of TRIBs with MEK1 to drive increased phosphorylation of ERK. 
Consistent with this, an R107L substitution in TRIB1 has been shown to increase both ERK phosphorylation 
and C/EBPα degradation in human Down syndrome-related acute megakaryocytic leukaemia beyond that 
observed in cells carrying wild type TRIB1[72] . Drug resistance has also been seen to be conferred by TRIB2-
related overexpression of anti-apoptotic BCL-2, which increases relapse and chemoresistance by promoting 
proliferation and blocking apoptosis[2]. 
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Analysis of publicly available RNAseq data from the Human Protein Atlas highlights the variability of TRIB 
expression across cancer subtypes, and the significant upregulation of TRIB family members in many. However 
it is important to note that both published[49] and unpublished data demonstrate that TRIB roles, and 
therefore suitability as a biomarker in disease, are more accurately related to protein expression levels and 
thus this differential expression must be confirmed and analysed at the protein level. 
TRIB dysregulation is not limited to cancer pathologies, and links have been shown between TRIB proteins and 
liver and metabolic syndromes[73], neurodegenerative disorders[74]and inflammatory disorders[75]. 
Multiple unbiased genome-wide association studies (GWAS) have demonstrated associations between TRIB1 
and plasmid lipid traits of relevance to cardiovascular disease[76,77]. Investigation into the role of TRIB3 in 
the progression of Parkinson’s disease identified upregulation of TRIB3 in human patients and cellular models, 
with overexpression in cells sufficient to promote neuronal cell death via interaction with the pro-survival 
protein Parkin[74]. By contrast, TRIB3 expression in diabetic kidney disease reduces inflammatory gene 
expression[78]. 
Potential roles of TRIB biomarkers  
Well-defined biomarkers are a crucial and powerful tool in disease classification, diagnosis, prognosis and 
clinical approach, emphasising the urgency for an ever-increasing library of biologically and clinically relevant 
markers. 
Given the differential expression of TRIB proteins noted across cancer subtypes (Error! Reference source not 
found.) and the previously discussed TRIB1 R107L mutation, as well as additional diseases such as antibody-
mediated allograft rejection[1], Parkinson’s Disease[74] and inflammation[38], it is easy to appreciate the 
benefit of these proteins as potential novel biomarkers of disease and treatment.  
TRIB2 has previously been reported as a biomarker for progression of melanoma[79], and multiple lines of 
investigation into its role in AML have supported its use as a biomarker of chemoresistance and relapse. In the 
AML cell line U937, elevated TRIB2 protein expression was demonstrated to directly correlate with high 
expression of the anti-apoptotic BCL-2 protein[2], which drives tumour survival and chemoresistance by 
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promoting proliferation and preventing apoptosis. Consequentially these cells were shown to be highly 
sensitive to BCL-2 inhibition with the BH3 mimetic Venetoclax and demonstrated synergistic killing when 
treated with a combination of Venetoclax and chemotherapy. This correlation of high TRIB2 and BCL-2 
expression was further demonstrated in approximately 25% of primary patient samples, indicating that these 
results have clinical as well as biological relevance. Thus, use of TRIB2 as a biomarker can identify subsets of 
AML cells which are primed for cell death either with BH3 mimetics alone or in combination with 
chemotherapy, and in turn help to stratify clinical approach by identifying patients who may benefit most from 
this line of treatment. 
Given the involvement of TRIB2 in the aetiology of cancers beyond AML, this observation raises an interesting 
question about the potential of TRIB2 as a marker in concurrence with BCL-2 elevation in other cancers. 
Existing data indicates high levels of BCL-2 expression in many cancers[80] including melanoma and lung 
cancer that exhibit high TRIB2 expression levels, and as such highlights the potential of TRIB2 as a biomarker 
for Venetoclax sensitivity in this context. 
TRIB2 has also been highlighted as conferring resistance to standard therapies and PI3K inhibitors via a PI3K 
network, activating AKT and thus ablating FOXO and p53 activation. This corresponds to clinical outcome in 
metastatic melanoma, primary pancreatic and primary colon tissue samples, with TRIB2 (though not TRIB1 or 
TRIB3) expression correlating with a significantly worse prognosis[23].  
Recently, TRIB3 expression in renal cell carcinoma was correlated with advanced tumour stage and 
unfavourable prognosis[67], with overexpression showing promotion of cell proliferation, migration, invasion 
and xenograft growth. Overexpression has also been positively correlated with VEGF-A expression and 
angiogenesis in gastric cancer[56], associated with a shorter survival time and higher incidence of recurrence 
and metastasis. In a pattern similar to TRIB2-related BCL-2 expression, this may highlight TRIB3 as a biomarker 
for subsets of patients who will be particularly receptive to treatment with VEGF-A inhibitors such as Votrient, 
which is currently used in the treatment of renal cell carcinoma. 
 12 
Taken together these data emphasize the suitability of TRIB proteins as biomarkers for prognosis and 
treatment feasibility, helping to individualize patient treatment. This potential role extends beyond cancer 
malignancies; as discussed previously, GWAS analyses have demonstrated associations between TRIB1 and 
circulating alanine transaminase[81], which may function as a potential biomarker of fatty liver disease[82], 
further underpinning this proposed role. It is also clear that this hypothesis is not limited to the TRIB family, 
as pseudokinase members of the receptor tyrosine kinase family including ROR1, PTK7 and RYK have been 
found to have variable expression in subtypes of healthy and malignant B and T cells, implicating these 
pseudoenzymes as potential biomarkers for diagnosis[83]. 
TRIBs as alternative therapeutic targets  
With their diverse functions in disease progression and prognosis, it is clear to see why TRIB pseudokinases 
also present an exciting possibility as therapeutic targets in addition to their function as biomarkers, and 
studies which have delineated the processes and pathways in which TRIBs are involved have also highlighted 
the therapeutic benefit of their depletion. In AML, TRIB2 depletion results in apoptosis, inhibited growth and 
cell cycle arrest[84], while in Parkinson’s disease TRIB3 knockdown protects neuronal cells from death[74]. 
High expression of TRIB3 and its correlation with VEGF-A in gastric cancer highlight it’s potential both as a 
biomarker as an antiangiogenic target[56]. Further, TRIB3 expression level was identified as a biomarker 
predicting the responsiveness to anti-acute promyelocytic leukaemia therapy and using tool peptide 
compounds to target TRIB3 protein interaction with PML-RAR enhanced anti-acute promyelocytic leukaemia 
therapy and had potent anti-leukemic efficacy[10].  
Despite this, pseudokinases have been largely unexplored as drug targets due to the associated challenges, 
and currently no clinically approved therapeutics exist which target them. However, studies in their kinase 
counterparts may prove to be beneficial in developing this line of investigation. Structural studies investigating 
the non-catalytic roles of kinases have broadened our understanding of the molecular mechanisms supporting 
these roles[4,85] and have outlined that many functions are regulated by conformational changes in the kinase 
structure. This supports the hypothesis that there may be similarities in some non-canonical functions 
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between kinases and their pseudokinase counterparts, thus directing interest towards these structural 
characteristics as therapeutic targets[4]. In line with this, studies using small molecule compounds have 
demonstrated stabilization of the inactive state KSR-1 pseudokinase which antagonizes RAF 
heterodimerization and downstream Ras signalling[86], and HER3-targeting molecules modulate 
heterodimerization with active epidermal growth factor receptors and initiate partial degradation of the HER3 
protein[12].  
The lack of available crystal structures for TRIB2 and TRIB3 impedes investigation of structural changes as 
‘druggable’ targets in these proteins, however the recently solved crystal structure of TRIB1 in complex with 
C/EBPα indicated that TRIB1 undergoes a substantial conformational change in its activation loop upon 
‘pseudosubstrate’ binding[15]. This conformational change releases the COP1 binding motif from a binding 
site on the αC helix of the pseudokinase domain, effectively releasing TRIB1 autoinhibition while 
simultaneously binding C/EBP transcription factors for degradation (Figure 2). This result emphasises a 
potential therapeutic target outside of the canonical ATP-binding pocket; compounds targeted towards the 
TRIB ‘active site’ which can either stabilize or destabilize their alternative conformations could prove potent 
in affecting the lifetime and function of TRIB proteins in cells[15]. 
While we have chosen here to focus on the use of kinase inhibitor drugs, additional therapeutic options such 
as peptides or monoclonal antibodies also pose promising opportunities for treatment. The Pep2-S160 fusion 
peptide, for example, was demonstrated to disrupt the interaction of TRIB3 with PML-RARα[10] and advances 
have been made in the targeting of intracellular tumour-related antigens via their presentation on the cell 
surface by MHC-I[87]. 
TRIBs as a novel target in drug repurposing 
The development of targeted therapy for cancer in recent years has produced a wide variety of anti-cancer 
compounds designed to target cancer-related molecules and signalling pathways. Of particular interest to the 
field of pseudokinases are kinase inhibitors, which bind to the ATP pocket and/or allosteric sites of oncogenic 
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kinases, impeding function with the goal of reducing aberrant growth factor signalling.  Interestingly, many of 
these pre-existing drugs target pathways in which TRIB proteins have been demonstrated to play a role. 
Repurposing of existing drugs presents a faster and more cost effective route of drug development than the 
development of novel compounds and thus recent studies have sought to investigate the potential of 
repurposing clinically approved drugs to seek out novel targets, including TRIB1 and TRIB2.  
A recent study by Foulkes et al demonstrated the efficacy of three ErbB covalent kinase inhibitors Afatinib, 
Neratinib and Osimertinib in binding to and destabilizing TRIB2 in vitro[61]. This activity was mediated via 
competitive covalent binding to the conserved Cys96 and/or Cys104 residue located in the vestigial ATP-binding 
site of TRIB2, which confers protein stability under normal physiological conditions. Upon binding of ErbB 
inhibitors to this residue, TRIB2 was destabilized due to the uncoupling of the C-terminal tail, resulting in TRIB2 
degradation facilitated by its own interactions with COP1. This demonstrates the dynamic nature of the 
docking of the C-terminal tail to the pseudokinase core, consistent with observations in kinase counterparts, 
and the potential of the vestigial ATP-binding domain as a novel target for TRIB2 inhibition. This study also 
highlights the potential of differential scanning fluorimetry (DSF) profiling in identifying clinically relevant 
secondary “on target” effects of currently approved drugs. 
Similarly, as part of their structural studies of TRIB1, Jamieson et al. utilized DSF screening of published kinase 
inhibitors to identify compounds which induced thermal stabilization of TRIB1 by more than 2°C[15], indicative 
of a stabilizing interaction with the protein. By this method several compounds were identified, originally 
designed for targeting of either the vascular endothelial growth factor receptors or epidermal growth factor 
receptors, indicating that a similar approach to drug repurposing could be utilised in the case of TRIB1. 
Additionally, the discovery of the “SLE-in” and “SLE-out” conformational changes of the TRIB1 activation loop 
upon substrate binding raises an interesting possibility for small molecule targeting of TRIB proteins by 
targeting these changes in order to lock the protein into either of these configurations.  
It should also be noted that in the emerging field of proteolysis-targeting chimeras (PROTACs), which exploits 
the endogenous proteasomes of cells by targeting proteins for degradation, structures often contain protein-
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binding regions derived from kinase inhibitors[88]. It stands to reason then that PROTAC technology may 
indeed be adapted or repurposed for the targeting of pseudokinases and indeed the TX2-121-1 HyT degrader 
results in degradation of the HER3 pseudokinase and induces cell death of HER3-dependent cell lines[89]. 
Conclusions and future questions  
We have highlighted existing research which provides evidence of TRIB proteins as a potential biomarker of 
disease progression and prognosis, with applications not only in cancer biology but in neurodegenerative and 
inflammatory disorders. Furthermore, we have outlined the potential of TRIB pseudokinases in stratifying 
patient treatment options. Whilst this has focused on the application of TRIB2 profiling in AML patients, it is 
clear that there are wider reaching implications for analysis of all TRIB proteins across varying cancer 
pathologies.  
Additionally, although we have focused primarily on the TRIB family, the broader scope of these principals 
should not be disregarded. The HER3 receptor tyrosine kinase, for example, lacks appreciable kinase activity 
but is associated with several cancers due to its role as an epidermal growth factor receptor heterodimeric 
partner[12], thus having potential as a pharmacological target and biomarker for its associated cancers. 
Moving forward it will be important to continue to recognize the roles of these ‘inactive’ proteins in order to 
identify those which may be employed as biomarkers in their associated conditions, and which can act as 
therapeutic targets. Furthermore, examination of the ability of existing drugs to target and diminish the 
activities of these proteins has the potential to yield important therapeutically-relevant results and aid in the 
improvement and ease of drug development and patient care. 
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Figure 1. Structure and function of TRIB pseudokinase, with TRIB2 as a representative example.  
An N-terminal PEST region mediates degradation to control protein turnover. A serine/threonine 
pseudokinase domain which lacks canonical kinase activity serves as a scaffolding region for substrate 
proteins, while the C-terminal region contains binding motifs for both MEK1 and COP1, mediating the MAPK 
pathway and E3 ubiquitin ligase respectively. Interactions with AKT have been demonstrated however the 
precise mechanisms of AKT regulation are unclear and vary between TRIBs. 
Figure 2.  Mechanism of action of TRIB1-mediated C/EBPα degradation by COP1. A) COP1-binding motif is 
bound to TRIB1 pseudokinase core in an autoinhibitory fashion.  B) C/EBPα binding to core induces 
conformational change and releases COP1-binding C-terminus. C) COP1 binds to C-terminus via WD40 
domain. D) COP1 mediates lysine ubiquitination of C/EBPα which is degraded by the proteasome. C/EBPα 
loss triggers release of COP1 by TRIB1 as inhibited conformation is resumed. 
Figure 3. TRIB interaction pathways. TRIB proteins are involved both directly and indirectly with pathways 
which influence differentiation, apoptosis, cell survival, inflammation and senescence.    
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TRIB Process Reference 
TRIB1 Liver function [25–28] 
TRIB1 Immunoglobulin production [29] 
TRIB1 Cell cycle control [30] 
TRIB2 ESC pluripotency [31] 
TRIB2 Thermogenesis [32] 
TRIB3 Adipogenesis [33] 
TRIB3 Glucose regulation [34] 
TRIB3 Cell cycle control [35] 
TRIB3 Neuronal apoptosis/autophagy [36] 
TRIB3 Lipid metabolism [37] 
TRIB1-
TRIB3 
Haematopoiesis [13,38–42] 
Table 1. Physiological roles of TRIB proteins in mammalian cells. 
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Cancer Protein Observations Kinase inhibitors Key references 
Acute promyelocytic 
leukaemia 
TRIB3 TRIB3 promotes progression and therapy 
resistance by suppressing PML-RARα 
degradation and inhibiting senescence. 
TRIB1 expression is decreased in human 
acute promyelocytic leukaemia. 
SU11657, PP2 [10,46–48] 
Breast TRIB1, TRIB3 TRIB1 is overexpressed in triple negative 
breast cancer and regulates NF-κB and AP1-
dependent transactivation of CCND1. 
 
TRIB3 overexpression confers good 
prognosis at the protein level, likely due to 
its inhibition of phospho-AKT. 
Lapatinib, Canertinib, 
Abemaciclib, Neratinib, 
Olaparib, Palbociclib, 
Ribociclib, Talazoparib 
[30,49] 
 27 
Chronic lymphocytic 
leukaemia 
TRIB1 Differential methylation in male vs female 
patients. Interactions with NF-κB pathway 
may contribute to more serious disease 
state in chronic lymphocytic leukaemia 
males. 
Duvelisib, Ibrutinib, 
Idelalisib, Duvelisib 
[50] 
Colorectal TRIB1, TRIB2 TRIB1 promotes cell migration via activation 
of MMP-2 via FAK/Src and ERK pathways. 
 
TRIB2 correlates with poor prognosis and 
blocks cellular senescence through AP4/p21 
signalling. Also promotes resistance to 
therapy by activating AKT. 
 
TRIB3 is upregulated and increases 
expression of stem cell-related genes via 
interaction with β-catenin and TCF4. 
Regorafenib, Vatalanib  [51–53] 
 28 
Endometrial  TRIB3 Suppresses proliferation and invasion and 
promotes apoptosis via decreased 
expression of MMP-2 and MMP-9. 
Lapatinib (with Trastuzumab 
Ab), Afatinib,  
[54] 
Thyroid TRIB1, TRIB3 Significant overexpression noted in gene 
profiling. 
Sorafenib, Lenvatinib [55] 
Gastric TRIB3 Tumour angiogenesis and a poor prognosis, 
correlation with expression of VEGF-A. 
Gefitinib, Erlotinib, 
Sorafenib, Sunitinib, 
Lapatinib 
[56] 
Glioma TRIB1 Plays a critical role in the development of 
radioresistance due to complex formation 
with phospho-HDAC1 to suppress p53. 
Imatinib  [57] 
Hepatocellular 
Carcinoma 
TRIB1 TRIB1 promotes hepatocellular carcinoma 
tumorigenesis and invasiveness via 
downregulation of p53. 
Sorafenib  [58] 
 29 
Leukaemia (myeloid) TRIB1, TRIB2, TRIB3 MLL-TET1 (MT1), Notch1 and E2F 
upregulate TRIB2 via promoter binding.  
 
TRIB2 maintains differentiation blockade of 
myeloid cells. Confers chemoresistance by 
activating AKT.  
 
Both TRIB1 and TRIB2 bind to and degrade 
C/EBPα, and enhance ERK phosphorylation. 
Bosutinib, Dasatinib, 
Enasidenib, Gilteritinib, 
Glasdegib, Imatinib, 
Ivosidenib, Midostaurin, 
Nilotinib, Ponatinib, 
Sunitinib, Afatinib, 
Osimertinib, Neratinib 
[13,20,41,59–61] 
Liver TRIB2 TRIB2 promotes tumorigenesis and cell 
survival through interaction with the βTrCP 
ubiquitin ligase and degradation of C/EBPα. 
Sorafenib,  [62] 
 30 
Non-small-cell lung 
cancer 
TRIB2, TRIB3 TRIB2 associates with TRIM21 E3 ligase to 
down-regulate C/EBPα. 
 
TRIB3 upregulation is associated with distal 
metastasis and disease recurrence, likely via 
Notch1/JAG signalling. 
Gefitinib, Canertinib, 
Vatalanib, Osimertinib, 
Erlotinib 
[63,64] 
Ovarian TRIB1, TRIB3 High TRIB1 expression was associated with 
a poorer survival rate likely due to activation 
of phospho-ERK. 
Niraparib, Olaparib, 
Rucaparib 
[65] 
Pancreatic TRIB2 Confers resistance to chemotherapy by 
activation of AKT pathway. 
Erlotinib [23] 
Prostate TRIB1 TRIB1 upregulation significantly associated 
with metastasis and poor prognosis. 
Nilotinib, Erlotinib, 
Lapatinib, Imatinib 
[66] 
Renal cell carcinoma TRIB3 Activated during hypoxia by HIF-1α and 
promotes cell proliferation, migration and 
invasion via MAPK. 
Sorafenib, Sunitinib, 
Pazopanib 
[67] 
Table 2. Roles of TRIB family proteins in cancer subtypes, with associated clinically trialled kinase inhibitors and key references.
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